Completed PHASE1 INTERVENTIONAL 1-arm NCT00145041

Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction

An Evaluation of the Pharmacokinetic Profile of VSLI (Vincristine Sulfate Liposome Injection, 0.16 mg/mL) in Patients With Malignant Melanoma and Hepatic Dysfunction Secondary to Metastases

Sponsor: Acrotech Biopharma Inc.

Conditions Malignant Melanoma

Interventions Vincristine Sulfate Liposomes Injection

Updated 11 times since 2017 Last updated: Dec 10, 2019 Started: Feb 28, 2005 Primary completion: Sep 30, 2007 Completion: Nov 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Malignant Melanoma and is currently completed. Acrotech Biopharma Inc. leads this study, which shows 11 recorded versions since 2005 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

11 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1
Nov 2022 — Dec 2022 [monthly]

Completed PHASE1

▶ Show 6 earlier versions

Dec 2021 — Nov 2022 [monthly]

Completed PHASE1
Jan 2021 — Dec 2021 [monthly]

Completed PHASE1
Jan 2020 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Jan 2020 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Feb 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Acrotech Biopharma Inc.

Data source: Acrotech Biopharma Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States